Two numbers describe the peptide trade with China — a customs total that mixes legal and gray trade, and a crypto trail that isolates the gray market. Both, with their definitions attached.
“U.S. imports of unregulated injectable chemicals from China doubled in 2025” — that sentence, from AsapSCIENCE’s June 2026 BPC-157 video, has been repeated by outlets and commenters ever since. The doubling is real. The description is not. This page keeps both of the trade’s real numbers side by side, with the definition of each printed next to it in the same size type — because in this story, the definition is the news.
Number one: the customs total — $164M → $328M
Source: The New York Times, January 3, 2026 ("‘Chinese Peptides’ Are the Tech World’s Latest Biohacking Fad"), citing U.S. customs data.
What the figure actually is: the dollar value of imports from China in a broad customs category of hormone and peptide compounds, comparing the first three quarters of 2024 ($164 million) with the first three quarters of 2025 ($328 million).
What the category contains: bulk active ingredients feeding legal demand — including GLP-1 active ingredients for U.S. compounding pharmacies operating in the regulated channel — alongside melanotan II, research chemicals, and gray-market supply. The category cannot separate a compounding pharmacy’s bulk order from a gray-market reshipper’s stock. It is a dollar value over nine months, not a full year, not a unit count, and not a count of anything “unregulated” or “injectable” specifically.
The honest sentence: Imports of hormone and peptide compounds from China — a category spanning legal pharmaceutical supply chains and the gray market alike — doubled in dollar value across the first nine months of 2025. Less quotable. Also true.
Number two: the crypto trail — $32M in one quarter
Source: Chainalysis, June 4, 2026 — blockchain analysis tracing payments to wallets the firm identifies as belonging to gray-market peptide vendors. (Attribution rests on Chainalysis’s own wallet labeling; we report it as the firm’s finding.)
- $32 million in cryptocurrency reached gray-market peptide vendor wallets in Q1 2026 alone — a 159% rise on Q4 2025, and an annualized run rate above $100 million.
- Through 2024, the same flow ran at roughly $1 million per quarter. The growth is not a doubling; it is a phase change.
- One Czech testing laboratory’s suspected wallets received $12 million or more since 2023 — the testing economy grows with the market it polices.
- Chainalysis also reports that average testing spend per buyer fell by roughly 88% even as volume exploded — buyers are spending less, proportionally, on verifying what they inject.
- Some vendor wallets Chainalysis traced had previously sold fentanyl and amphetamine precursors (the firm’s attribution, labeled as such) — the gray market’s supply chains are not peptide specialists.
Why this is the sharper measure: it counts money arriving at identified gray-market sellers, not a customs category that sweeps in the legal trade. When someone cites a number for “the gray market,” this is the series that measures it.
Why the supply concentrates in China and India
Peptide active ingredients are not extracted; they are manufactured — built amino acid by amino acid, then purified and verified (see Where Do Peptides Come From?). That manufacturing has concentrated where chemical-synthesis capacity, purification infrastructure, and cost structure meet: overwhelmingly China, with India second. Our census research (November 2026) counted 74 of the 90 FDA drug master files for semaglutide active ingredient — 82% — held by Chinese manufacturers. The concentration is not a conspiracy and not unique to gray-market goods; it is the same industrial geography the legal pharmaceutical supply chain runs on. What the gray market adds is a retail layer — websites, reshippers, conference booths — between that industrial base and individual buyers, with no quality gate in between.
What arrives is not always what the label says
The quality record, from the two best datasets available:
- Janvier, Vanhee et al. (Talanta, 2018) — a Belgian public-health laboratory analyzed the ten most frequently encountered falsified peptide drugs seized from illegal internet pharmacies (ipamorelin, CJC-1295, thymosin beta-4, sermorelin, GHRP-2, GHRP-6, AOD-9604, epithalon, oxytocin, melanotan II — note: BPC-157 was not among them): purity as low as 5–75% for some compounds, 30% of samples with incorrect amino-acid sequences, two-thirds below 95% purity, inorganic arsenic at up to ten times the limit for injectable drugs, lead above the toxicity threshold in at least one sample.
- Mendias & Awan (2026) — a re-analysis of 6,441 consumer-market samples from 203 vendors found 41.6% to 71.1% failed basic quality standards, depending on whether a compounding or manufacturing standard was applied; 15% of samples tested for endotoxin had measurable levels.
- Finnrick Analytics — across 7,000+ samples, roughly one in three fail basic expectations; for BPC-157 specifically (469 samples, 69 vendors), the failures are chiefly wrong quantity (up to ±80% of label) and endotoxin (~8% of samples).
That is the documented cost of an ungated supply chain — not the customs total, and not a slogan about any one country.
Read next
- Where Do Peptides Come From? (And Could You Make Your Own?)
- AsapSCIENCE Took On BPC-157. We Checked Every Claim.
- Contaminated Products & Forged Lab Reports
- Testing
Educational information only — not medical or legal advice. Figures as reported by the sources cited, November 9, 2026. See Our Legal Mandate.